SMT202200338T1 - Acidi propionici 3-sostituiti come inibitori delle integrine alfa v - Google Patents
Acidi propionici 3-sostituiti come inibitori delle integrine alfa vInfo
- Publication number
- SMT202200338T1 SMT202200338T1 SM20220338T SMT202200338T SMT202200338T1 SM T202200338 T1 SMT202200338 T1 SM T202200338T1 SM 20220338 T SM20220338 T SM 20220338T SM T202200338 T SMT202200338 T SM T202200338T SM T202200338 T1 SMT202200338 T1 SM T202200338T1
- Authority
- SM
- San Marino
- Prior art keywords
- alpha
- propionic acids
- integrin inhibitors
- substituted propionic
- substituted
- Prior art date
Links
- -1 3-substituted propionic acids Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000006495 integrins Human genes 0.000 title 1
- 108010044426 integrins Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662418848P | 2016-11-08 | 2016-11-08 | |
| EP17801230.8A EP3538525B1 (en) | 2016-11-08 | 2017-11-07 | 3-substituted propionic acids as alpha v integrin inhibitors |
| PCT/US2017/060376 WO2018089353A1 (en) | 2016-11-08 | 2017-11-07 | 3-substituted propionic acids as alpha v integrin inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202200338T1 true SMT202200338T1 (it) | 2022-09-14 |
Family
ID=60409432
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20220338T SMT202200338T1 (it) | 2016-11-08 | 2017-11-07 | Acidi propionici 3-sostituiti come inibitori delle integrine alfa v |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US10968219B2 (enExample) |
| EP (1) | EP3538525B1 (enExample) |
| JP (1) | JP7097358B2 (enExample) |
| KR (1) | KR102505629B1 (enExample) |
| CN (1) | CN110167935B (enExample) |
| AR (1) | AR110153A1 (enExample) |
| AU (1) | AU2017359023B2 (enExample) |
| CA (1) | CA3042707A1 (enExample) |
| CL (1) | CL2019001264A1 (enExample) |
| CO (1) | CO2019005824A2 (enExample) |
| DK (1) | DK3538525T3 (enExample) |
| EA (1) | EA038164B1 (enExample) |
| ES (1) | ES2925173T3 (enExample) |
| HR (1) | HRP20220990T1 (enExample) |
| HU (1) | HUE059708T2 (enExample) |
| IL (1) | IL266473B (enExample) |
| LT (1) | LT3538525T (enExample) |
| MA (1) | MA46743A (enExample) |
| MX (1) | MX380799B (enExample) |
| MY (1) | MY199931A (enExample) |
| NZ (1) | NZ754207A (enExample) |
| PE (1) | PE20191647A1 (enExample) |
| PL (1) | PL3538525T3 (enExample) |
| PT (1) | PT3538525T (enExample) |
| RS (1) | RS63483B1 (enExample) |
| SI (1) | SI3538525T1 (enExample) |
| SM (1) | SMT202200338T1 (enExample) |
| TW (1) | TWI763733B (enExample) |
| WO (1) | WO2018089353A1 (enExample) |
| ZA (1) | ZA201903665B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201823208A (zh) | 2016-09-07 | 2018-07-01 | 美商普萊恩醫療公司 | N－醯基胺基酸化合物及其使用方法 |
| PL3538525T3 (pl) * | 2016-11-08 | 2022-09-12 | Bristol-Myers Squibb Company | 3-podstawione kwasy propionowe jako inhibitory integryny alfa v |
| BR112019009245A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | azol amidas e aminas como inibidores de alfav integrina |
| BR112019009129A2 (pt) * | 2016-11-08 | 2019-07-16 | Bristol-Myers Squibb Company | compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina |
| MX2019007797A (es) | 2016-12-29 | 2019-10-21 | Univ Saint Louis | Antagonistas de integrinas. |
| CN116283977A (zh) | 2017-02-28 | 2023-06-23 | 莫菲克医疗股份有限公司 | αvβ6整合蛋白的抑制剂 |
| EP3589285A4 (en) | 2017-02-28 | 2020-08-12 | Morphic Therapeutic, Inc. | INHIBITORS OF INTEGRIN (ALPHA-V) (BETA-6) |
| SG11202101913PA (en) | 2018-08-29 | 2021-03-30 | Morphic Therapeutic Inc | INHIBITING aV ß6 INTEGRIN |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| CN109824495B (zh) * | 2019-02-02 | 2022-12-09 | 盐城师范学院 | 一种新型偶联反应在制备碳-碳键结构化合物中的应用 |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| GB202010626D0 (en) | 2020-07-10 | 2020-08-26 | Univ Nottingham | Compound |
| WO2025064802A1 (en) * | 2023-09-21 | 2025-03-27 | Morphic Therapeutic, Inc. | INHIBITING HUMAN INTEGRIN α5β1 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0451790A1 (de) * | 1990-04-12 | 1991-10-16 | Hoechst Aktiengesellschaft | 3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung |
| US5849736A (en) | 1993-11-24 | 1998-12-15 | The Dupont Merck Pharmaceutical Company | Isoxazoline and isoxazole fibrinogen receptor antagonists |
| ZA972195B (en) | 1996-03-15 | 1998-09-14 | Du Pont Merck Pharma | Spirocycle integrin inhibitors |
| IL136267A0 (en) | 1997-11-26 | 2001-05-20 | Du Pont Pharm Co | 1,3,4-THIADIZOLES AND 1,3,4-OXADIAZOLES AS αVβ3 ANTAGONISTS |
| JP2002508323A (ja) | 1997-12-17 | 2002-03-19 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| JP2002522540A (ja) * | 1998-08-13 | 2002-07-23 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
| US6855722B2 (en) | 2001-01-29 | 2005-02-15 | Dimensional Pharmaceuticals, Inc. | Substituted indoles and their use as integrin antagonists |
| WO2004058254A1 (en) * | 2002-12-20 | 2004-07-15 | Pharmacia Corporation | Heteroarylalkanoic acids as integrin receptor antagonists |
| BR0316875A (pt) * | 2002-12-20 | 2005-10-25 | Pharmacia Corp | Compostos de pirazol como derivados antagonistas receptores da integrina, sua composição farmacêutica e respectivo uso |
| WO2006108040A1 (en) | 2005-04-05 | 2006-10-12 | Janssen Pharmaceutica, N.V. | Substituted indoles and their use as integrin antagonists |
| TW200800999A (en) * | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| AR059224A1 (es) | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| JP2009539815A (ja) | 2006-06-09 | 2009-11-19 | アストラゼネカ アクチボラグ | 固形腫瘍の治療用のａ５ｂ１アンタゴニストとしてのＮ−（ベンゾイル）−Ｏ−［２−（ピリジン−２−イルアミノ）エチル］−Ｌ−チロシン誘導体と関連化合物 |
| WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| JP2013503834A (ja) | 2009-09-04 | 2013-02-04 | ビーエーエスエフ ソシエタス・ヨーロピア | １−フェニルピラゾールの製造方法 |
| CA2779303A1 (en) | 2009-10-29 | 2011-05-19 | Sirtris Pharmaceuticals, Inc. | Bicyclic pyridines and analogs as sirtuin modulators |
| ITFI20100019A1 (it) | 2010-02-12 | 2011-08-13 | Univ Firenze | Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori. |
| GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| CA2976634C (en) | 2015-02-19 | 2023-10-17 | Scifluor Life Sciences, Inc | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
| WO2016145258A1 (en) * | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| PL3538525T3 (pl) * | 2016-11-08 | 2022-09-12 | Bristol-Myers Squibb Company | 3-podstawione kwasy propionowe jako inhibitory integryny alfa v |
-
2017
- 2017-11-07 PL PL17801230.8T patent/PL3538525T3/pl unknown
- 2017-11-07 SI SI201731195T patent/SI3538525T1/sl unknown
- 2017-11-07 EA EA201991122A patent/EA038164B1/ru unknown
- 2017-11-07 RS RS20220759A patent/RS63483B1/sr unknown
- 2017-11-07 HR HRP20220990TT patent/HRP20220990T1/hr unknown
- 2017-11-07 AU AU2017359023A patent/AU2017359023B2/en active Active
- 2017-11-07 JP JP2019523576A patent/JP7097358B2/ja active Active
- 2017-11-07 EP EP17801230.8A patent/EP3538525B1/en active Active
- 2017-11-07 LT LTEPPCT/US2017/060376T patent/LT3538525T/lt unknown
- 2017-11-07 NZ NZ754207A patent/NZ754207A/en unknown
- 2017-11-07 WO PCT/US2017/060376 patent/WO2018089353A1/en not_active Ceased
- 2017-11-07 MA MA046743A patent/MA46743A/fr unknown
- 2017-11-07 MY MYPI2019002576A patent/MY199931A/en unknown
- 2017-11-07 KR KR1020197016082A patent/KR102505629B1/ko active Active
- 2017-11-07 PE PE2019000940A patent/PE20191647A1/es unknown
- 2017-11-07 ES ES17801230T patent/ES2925173T3/es active Active
- 2017-11-07 MX MX2019005244A patent/MX380799B/es unknown
- 2017-11-07 CN CN201780082473.2A patent/CN110167935B/zh active Active
- 2017-11-07 CA CA3042707A patent/CA3042707A1/en active Pending
- 2017-11-07 PT PT178012308T patent/PT3538525T/pt unknown
- 2017-11-07 US US16/347,844 patent/US10968219B2/en active Active
- 2017-11-07 SM SM20220338T patent/SMT202200338T1/it unknown
- 2017-11-07 HU HUE17801230A patent/HUE059708T2/hu unknown
- 2017-11-07 DK DK17801230.8T patent/DK3538525T3/da active
- 2017-11-08 TW TW106138533A patent/TWI763733B/zh active
- 2017-11-08 AR ARP170103105A patent/AR110153A1/es unknown
-
2019
- 2019-05-06 IL IL266473A patent/IL266473B/en unknown
- 2019-05-08 CL CL2019001264A patent/CL2019001264A1/es unknown
- 2019-06-04 CO CONC2019/0005824A patent/CO2019005824A2/es unknown
- 2019-06-07 ZA ZA2019/03665A patent/ZA201903665B/en unknown
-
2021
- 2021-02-24 US US17/184,179 patent/US11884661B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201903665B (en) | 3-substituted propionic acids as alpha v integrin inhibitors | |
| EP3193608A4 (en) | Carm1 inhibitors and uses thereof | |
| EP3200588A4 (en) | Arginine methyltransferase inhibitors and uses thereof | |
| EP3193611A4 (en) | Mk2 inhibitors and uses thereof | |
| EP3175023A4 (en) | Systems and methods for determining nucleic acids | |
| EP3134536A4 (en) | Systems and methods for barcoding nucleic acids | |
| IL267239A (en) | New derivatives of phenylpropionic acid and their uses | |
| EP3190682A4 (en) | Power supply system and method | |
| PL3218378T3 (pl) | Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych | |
| EP3229899A4 (en) | Methods and apparatus for electrosurgical illumination and sensing | |
| EP3181085A4 (en) | Tracking system and tracking method using same | |
| EP3153561A4 (en) | Composition for heat cycle system and heat cycle system | |
| EP3153567A4 (en) | Composition for heat cycle system and heat cycle system | |
| EP3162276A4 (en) | System and method for managing endoscopic scope | |
| EP3102189A4 (en) | Composition and method for aiding sleep | |
| EP3238840A4 (en) | Method for recycling used absorbent article | |
| EP3166523A4 (en) | Cryoablation method and system | |
| EP3141930A4 (en) | Distance-measurement device and method for powering distance-measurement device | |
| EP3232039A4 (en) | Method and device for energy-saving ship navigation | |
| EP3155399A4 (en) | Viscometer and methods for using the same | |
| EP3387192A4 (en) | APPARATUS FOR SANITARY PURPOSES AND WATER SUPPLY | |
| EP3195129A4 (en) | Application centric distributed storage system and method | |
| IL255054A0 (en) | Tetrahydronephthyridinyl propionic acid derivatives and their uses | |
| EP3185880A4 (en) | Improved peptidyl calcineurin inhibitors | |
| EP3139918A4 (en) | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors |